A directional attenuated vaccinia virus vaccine

By deleting the TK, F4L and B2R genes and inserting a promoter, the recombinant vaccinia virus VTT-dB/T/F was constructed, which solved the problems of high toxicity and poor immune effect of vaccinia virus and achieved a recombinant vaccinia virus with low toxicity and high immunogenicity. It is suitable for preventing poxviridae virus infections and as a vaccine vector.

CN115927215BActive Publication Date: 2025-10-17INST OF PATHOGEN BIOLOGY CHINESE ACADEMY OF MEDICAL SCI
3 Cites 0 Cited by

Patent Information

Application Number
CN202310080294.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-01-18
Publication Date
2025-10-17
Estimated Expiration
2043-01-18

AI Technical Summary

Technical Problem

Existing vaccinia virus vaccines are highly toxic, resulting in significant side effects, and their immune effects are inferior to those of replication-deficient strains. They are difficult to replicate in mammalian cells and require booster immunization or high-dose use to achieve immune effects.

Method used

By deleting the TK gene, F4L gene and B2R gene based on the Tiantan strain of vaccinia virus, a recombinant vaccinia virus was constructed. Gene editing was performed using homologous recombination, and the p11 and p7.5 promoters were inserted to form the recombinant vaccinia virus VTT-dB/T/F, which reduced toxicity and maintained complete replication ability.

Benefits of technology

The recombinant vaccinia virus with low toxicity and high immunogenicity can replicate completely in mammalian cells, activate a strong innate immune response, reduce side effects and improve immune effects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present application relates to a kind of recombinant vaccinia virus and its use, which is deleted at least one of TK gene, F4L gene and B2R gene relative to vaccinia virus Tianlu strain.The recombinant vaccinia virus of the present application has the characteristics of low toxicity, can be completely replicated and has higher immunogenicity.Therefore, the recombinant vaccinia virus provided by the present application has higher safety and enhanced immunogenicity.The recombinant vaccinia virus provided by the present application has higher application value as vaccine, can be used for preventing the infection of poxviridae virus, and as virus vector for constructing other infectious disease vaccine and tumor vaccine etc..
Need to check novelty before this filing date? Find Prior Art